Literature DB >> 7547640

Increased platelet phospholipase A2 activity in schizophrenia.

W F Gattaz1, A Schmitt, A Maras.   

Abstract

The intracellular enzyme phospholipase A2 (PLA2) plays an essential role in the breakdown of membrane phospholipids, which regulate the physicochemical properties of the cell membrane. In the brain PLA2 has been reported to influence receptor function and signal transduction. Regarding dopaminergic neurons, data from animals experiments and from binding studies suggest that PLA2 activation reduces dopaminergic neurotransmission. In the present study we investigated intracellular PLA2 in platelets from 31 DSM-III-R paranoid schizophrenic patients (15 neuroleptic-naive) compared to 31 healthy individuals and to 31 non-schizophrenic psychiatric controls, both matched to the schizophrenics by age and sex. Platelet PLA2 activity was significantly increased in schizophrenics as compared to healthy and to psychiatric controls. Neuroleptic treatment reduced significantly the enzyme activity. Our findings in platelets suggest an accelerated breakdown of membrane phospholipids in schizophrenia. An accelerated phospholipid breakdown has also been reported in the frontal cortex from schizophrenic patients. Further studies should clarify whether increased PLA2 in the brain, as observed in platelets, could contribute to a frontal dysfunction in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547640     DOI: 10.1016/0920-9964(94)00060-l

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  25 in total

1.  An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?

Authors:  Ramadhan Oruch; Anders Lund; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2010-01-27

2.  Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study.

Authors:  Prachi Semwal; Suman Prasad; Panchami G Varma; A M Bhagwat; S N Deshpande; B K Thelma
Journal:  J Genet       Date:  2002-08       Impact factor: 1.166

Review 3.  Platelet biomarkers in Alzheimer's disease.

Authors:  Leda L Talib; Helena Pg Joaquim; Orestes V Forlenza
Journal:  World J Psychiatry       Date:  2012-12-22

4.  Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples.

Authors:  K V Chowdari; B Brandstaetter; P Semwal; T Bhatia; S Deshpande; R Reddy; J Wood; C R Weinberg; B K Thelma; V L Nimgaonkar
Journal:  Psychiatr Genet       Date:  2001-12       Impact factor: 2.458

5.  Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia.

Authors:  J Brunner; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.

Authors:  Stefan Smesny; Susan Stein; Ingo Willhardt; Jürgen Lasch; Heinrich Sauer
Journal:  J Neural Transm (Vienna)       Date:  2008-06-27       Impact factor: 3.575

Review 7.  Platelets: A possible glance into brain biological processes in schizophrenia.

Authors:  Eyal Asor; Dorit Ben-Shachar
Journal:  World J Psychiatry       Date:  2012-12-22

8.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

9.  Deficit in prepulse inhibition in mice caused by dietary n-3 fatty acid deficiency.

Authors:  Irina Fedorova; Anita R Alvheim; Nahed Hussein; Norman Salem
Journal:  Behav Neurosci       Date:  2009-12       Impact factor: 1.912

Review 10.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.